Pharma BD Deal Intelligence
Proxygen's separate 2022 strategic collaboration with Merck KGaA (up to EUR495M / ~$554M) - a DIFFERENT company from Merck & Co/MSD. Documented to disambiguate…
Proxygen will receive an upfront payment and be eligible for future payments of up to $2.55 billion.
Proxygen's own milestone timeline. Confirms the April 2023 MSD deal is the only Merck & Co agreement (no post-2023 MSD expansion) and records platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck entered a multi-year collaboration with Proxygen to discover and develop novel molecular glue degraders against multiple therapeutic targets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Proxygen GmbH (this deal) | 2023 | $2.5B | 63 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals